Abstract Search

ea0063gp210 | Diabetes: Pharmacotherapy | ECE2019

Empagliflozin inhibits apoptosis of pancreatic beta-cells through amelioration of ER-stress.

Nasiri-Ansari Narjes , Dimitriadis Georgios K. , Angelousi Anna , Tsara Anna , Lembesis Panayiotis , Kiaris Hippokrates , Papavassiliou Athanasios G. , Randeva Harpal S. , Kassi Eva

Introduction: Type 2 diabetes mellitus (T2DM) is characterized by progressive impairment/ loss of pancreatic beta cell function Activation of endoplasmic reticulum (ER) stress by glucose variation has been suggested as an essential step towards beta cell dysfunction. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are widely used in the treatment of T2DM considering their beneficial cardiometabolic sequalae. In the present study, we aimed to investigate the effect of Empag...

0 shares

ea0063gp40 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Long-term administration of Empagliflozin may promote hepatic and renal lipid accumulation, and inflammation in the APOE knockout model

Tsara Anna , Nasiri-Ansari Narjes , Dimitriadis Georgios K , Theocharis Stamatis , Karapanagioti1 Angeliki , Danas Eougken , Papavassiliou Athanasios G , Randeva Harpal S , Kassi Eva

Introduction: Metabolic disorders characterized by insulin resistance/hyperinsulinemia, such as metabolic syndrome and T2DM, are associated with Non-Alcoholic Fatty Liver Disease (NAFLD). SGLT-2i reduce reabsorption of glucose from the kidneys thereby promoting glucosuria, while their beneficial effects on insulin resistance have been recently recognized. In this study, we aimed to investigate the effect of Empagliflozin, in de novo triglyceride synthesis and beta-oxi...

0 shares

Endocrine Abstracts

Empagliflozin inhibits apoptosis of pancreatic beta-cells through amelioration of ER-stress.

Long-term administration of Empagliflozin may promote hepatic and renal lipid accumulation, and inflammation in the APOE knockout model

BiosciAbstracts